Ewha Med J.  1990 Jun;13(2):93-100. 10.12771/emj.1990.13.2.93.

Improvement of Insulin Secretoruy Capacity According to Insulin Therapy in Non-Insulin Depentent Diabetes Mellitus

• Kyung NH

• KMID: 1965218
• DOI: http://doi.org/10.12771/emj.1990.13.2.93

Abstract

To evaluate whether the urinary and serum c-peptide is the indicator of insulin therapy in NIDDM, and whether the insulin secretery capacity improves after control of blood glucose, We measured 24 hour urinary c-peptide excretion, fasting and postprandial 2hour's serum c-peptide concentrations before and after insulin therapy in 20 patients with NIDDM. The results were as follows ; 1) The postprandial 2 hour's serum c-peptide level was significantly lower in patients with NIDDM than normal controls, bu t fasting serum c-peptide level and 24hour urinary c-peptide excretion showed no significant difference between normal control group and patients with NIDDM 2) There was no significant difference in duration of disease, body mass index, fasting serum c-peptide level and 24 hour urinary c-peptide excretion between insulin-requiring group and non-insulin-requiring group among patients with NIDDM. But post prandial 2 hour's serum c-peptide level was significantly lower in insulin requiring group than non-insulin-requiring group before treatment. 3) After therapy with insulin, post prandial 2 hour's serum c-peptide level increased significantly in insulin requiring group, but fasting serum c-peptide and 24 hour urinary c-peptide excretion were not changed significantly after therapy with insulin comparing with the level before therapy. Author concluded that postprandial 2 hour's serum c-peptide level was a market of insulin therapy in patients with NIDDM and insulin secretory capacity improved after controlling of blood glucose.

MeSH Terms

Blood Glucose
Body Mass Index
C-Peptide
Diabetes Mellitus*
Diabetes Mellitus, Type 2
Fasting
Humans
Insulin*
Blood Glucose
C-Peptide
Insulin